Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SA100 in ulcerative colitis
NCT02442960Phase 1Completed
- Sponsor
- Stanford University
- Start
- Dec 2014
- Primary completion
- Jul 2017
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 1, open-label trial of SA100 in ulcerative colitis (UC) (2 cohorts), sponsored by Stanford University. Primary endpoint: Safety and tolerability of herbal treatment (SA100) at 12 weeks. Started Dec 2014; status: completed.
02
Drugs
SA100
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02442960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442960.